Direct Inactivation of Human Immunodeficiency Virus Type 1 by a Novel Small-Molecule Entry Inhibitor, DCM205

Duong, Yen T; Meadows, D. Christopher; Srivastava, Indresh K.; Gervay‐Hague, Jacquelyn; North, Thomas W.

doi:10.1128/aac.01001-06

Cited by 8 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DCM205 (University of California) is a small-molecule entry inhibitor that can interfere with viral-host CD4 binding by interacting with the v3 loop on the gp120 of the virus. Binding to the virus occurs without the presence of the host target cell, and it is being considered in the development of a topical microbiocide [14] Fig. (2).…”

Section: Cd4 -Gp120 Binding Inhibitorsmentioning

confidence: 99%

Targeting HIV: Past, Present and Future

Zeier

Nachega

2011

IDDT

View full text Add to dashboard Cite

Since the identification of the human immunodeficiency virus (HIV) as the cause of the syndrome of acquired immunodeficiency syndrome (AIDS), there has been an evolution of compounds targeting the replication of the virus in an effort to delay clinical progression. In this review, we revise the mechanism of action of the different groups of drugs. We shortly revisit the older and perhaps lesser used as well as the more recently approved drugs and mention some of the compounds still under investigation.

show abstract

Section: Cd4 -Gp120 Binding Inhibitorsmentioning

confidence: 99%

Targeting HIV: Past, Present and Future

Zeier

Nachega

2011

IDDT

View full text Add to dashboard Cite

show abstract

“…For example, another low-molecular-weight inhibitor (DCM205) that binds to the V3 loop region of gp120 without competing with CD4 has been recently identified [18,19]. Also, a monoclonal antibody (TNX-355) binds to domain 2 of the CD4 receptor and inhibits gp120 in a noncompetitive fashion, allosterically blocking the conformational changes in gp120 that are necessary for cell fusion [20].…”

Section: Allosteric Inhibitorsmentioning

confidence: 99%

Strategies for Targeting HIV-1 Envelope Glycoprotein Gp120 in the Development of New Antivirals

Schön

Freire

2007

Future HIV Ther.

View full text Add to dashboard Cite

The efficacy of highly active antiretroviral therapy for the treatment of HIV-1/AIDS is continuously threatened by viral mutations that lower the potency of one or more of its components and by the occurrence of severe side effects that lead to poor patient compliance. There is an urgent need for the development of drugs against new viral targets. Among the most attractive targets for drug development is the viral envelope glycoprotein gp120, responsible for the initial step in viral infection. gp120 binds to the cell surface receptor CD4 and initiates the cascade of events that culminates with the entry of the virus into the cell. Two classes of drugs are being developed against gp120, drugs that block the attachment of the virus and drugs that inhibit the subsequent activation mechanism. Both approaches are discussed in this article.

show abstract

Survey of the year 2007 commercial optical biosensor literature

Rich

Myszka

2008

J of Molecular Recognition

166

121

View full text Add to dashboard Cite

In 2007, 1179 papers were published that involved the application of optical biosensors. Reported developments in instrument hardware, assay design, and immobilization chemistry continue to improve the technology's throughput, sensitivity, and utility. Compared to recent years, the widest range of platforms, both traditional format and array-based, were used. However, as in the past, we found a disappointingly low percentage of well-executed experiments and thoughtful data interpretation. We are alarmed by the high frequency of suboptimal data and over-interpreted results in the literature. Fortunately, learning to visually recognize good--and more importantly, bad--data is easy. Using examples from the literature, we outline several features of biosensor responses that indicate experimental artifacts versus actual binding events. Our goal is to have everyone, from benchtop scientists to project managers and manuscript reviewers, become astute judges of biosensor results using nothing more than their eyes.

show abstract

Direct Inactivation of Human Immunodeficiency Virus Type 1 by a Novel Small-Molecule Entry Inhibitor, DCM205

Cited by 8 publications

References 36 publications

Targeting HIV: Past, Present and Future

Targeting HIV: Past, Present and Future

Strategies for Targeting HIV-1 Envelope Glycoprotein Gp120 in the Development of New Antivirals

Survey of the year 2007 commercial optical biosensor literature

Contact Info

Product

Resources

About